Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Shares Purchased by Kendall Capital Management

Kendall Capital Management lifted its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 31.6% during the fourth quarter, Holdings Channel reports. The fund owned 17,760 shares of the specialty pharmaceutical company’s stock after buying an additional 4,260 shares during the quarter. Kendall Capital Management’s holdings in Collegium Pharmaceutical were worth $509,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Amundi grew its position in Collegium Pharmaceutical by 188.3% during the fourth quarter. Amundi now owns 15,568 shares of the specialty pharmaceutical company’s stock valued at $446,000 after buying an additional 10,168 shares during the period. Raymond James Financial Inc. acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $2,432,000. Aigen Investment Management LP acquired a new stake in Collegium Pharmaceutical during the fourth quarter valued at $230,000. Versor Investments LP grew its position in Collegium Pharmaceutical by 36.2% during the fourth quarter. Versor Investments LP now owns 19,582 shares of the specialty pharmaceutical company’s stock valued at $561,000 after buying an additional 5,200 shares during the period. Finally, Sanctuary Advisors LLC grew its position in Collegium Pharmaceutical by 5.3% during the fourth quarter. Sanctuary Advisors LLC now owns 18,928 shares of the specialty pharmaceutical company’s stock valued at $542,000 after buying an additional 952 shares during the period.

Collegium Pharmaceutical Stock Performance

NASDAQ:COLL opened at $28.91 on Monday. The company’s 50-day moving average price is $30.78 and its 200-day moving average price is $33.19. The company has a current ratio of 0.97, a quick ratio of 0.88 and a debt-to-equity ratio of 3.43. The company has a market cap of $910.26 million, a P/E ratio of 12.46 and a beta of 0.99. Collegium Pharmaceutical, Inc. has a twelve month low of $27.28 and a twelve month high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last posted its quarterly earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, topping the consensus estimate of $1.54 by $0.09. The firm had revenue of $181.95 million for the quarter, compared to the consensus estimate of $179.68 million. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. On average, sell-side analysts forecast that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other Collegium Pharmaceutical news, EVP Shirley R. Kuhlmann sold 40,000 shares of Collegium Pharmaceutical stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the transaction, the executive vice president now directly owns 154,204 shares of the company’s stock, valued at $4,330,048.32. The trade was a 20.60 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Insiders have sold 93,567 shares of company stock valued at $2,774,710 over the last ninety days. Company insiders own 3.98% of the company’s stock.

Analysts Set New Price Targets

COLL has been the topic of several analyst reports. Needham & Company LLC upgraded shares of Collegium Pharmaceutical from a “hold” rating to a “buy” rating and set a $46.00 price target on the stock in a research report on Friday, January 10th. HC Wainwright restated a “buy” rating and set a $50.00 price target on shares of Collegium Pharmaceutical in a research report on Friday, January 10th. Finally, Piper Sandler dropped their price target on shares of Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 4th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to MarketBeat.com, Collegium Pharmaceutical has an average rating of “Moderate Buy” and an average price target of $43.60.

Collegium Pharmaceutical Company Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.